John W. Kugler

5.9k total citations · 2 hit papers
62 papers, 4.5k citations indexed

About

John W. Kugler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, John W. Kugler has authored 62 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 13 papers in Surgery. Recurrent topics in John W. Kugler's work include Colorectal Cancer Treatments and Studies (16 papers), Lung Cancer Research Studies (15 papers) and Lung Cancer Treatments and Mutations (10 papers). John W. Kugler is often cited by papers focused on Colorectal Cancer Treatments and Studies (16 papers), Lung Cancer Research Studies (15 papers) and Lung Cancer Treatments and Mutations (10 papers). John W. Kugler collaborates with scholars based in United States and Canada. John W. Kugler's co-authors include Charles L. Loprinzi, James A. Mailliard, Paul J. Novotny, Al B. Benson, Daniel G. Haller, Paul J. Catalano, James P. Thomas, Jordan Berlin, Bradley J. Christensen and Kendrith M. Rowland and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

John W. Kugler

62 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297

2002 602 citations John W. Kugler et al. Journal of Clinical Oncology profile →
Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial

2000 539 citations Charles L. Loprinzi, John W. Kugler et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John W. Kugler United States	32	2.6k	1.4k	703	605	516	62	4.5k
Philip J. Stella United States	39	3.3k 1.3×	2.1k 1.5×	1.0k 1.4×	780 1.3×	470 0.9×	126	5.6k
Tom R. Fitch United States	34	2.0k 0.8×	1.3k 0.9×	1.2k 1.7×	813 1.3×	763 1.5×	97	4.6k
Loren K. Tschetter United States	32	2.2k 0.8×	1.1k 0.8×	507 0.7×	306 0.5×	603 1.2×	61	3.7k
Johannes M.G. Bonfrèr Netherlands	33	1.4k 0.5×	994 0.7×	1.1k 1.6×	463 0.8×	467 0.9×	67	4.1k
Janet L. Stanford United States	26	1.1k 0.4×	817 0.6×	783 1.1×	659 1.1×	611 1.2×	45	3.4k
J A Mailliard United States	35	4.6k 1.7×	1.9k 1.3×	721 1.0×	450 0.7×	1.9k 3.6×	60	6.7k
Seiichiro Yamamoto Japan	31	1.8k 0.7×	620 0.4×	1.2k 1.7×	519 0.9×	377 0.7×	60	4.0k
Peyman Hadji Germany	37	3.9k 1.5×	936 0.7×	1.1k 1.5×	769 1.3×	759 1.5×	167	5.8k
Lori C. Sakoda United States	36	1.4k 0.5×	1.2k 0.9×	1.2k 1.7×	927 1.5×	962 1.9×	125	4.1k
Darcy Spicer United States	29	2.0k 0.8×	675 0.5×	880 1.3×	813 1.3×	163 0.3×	91	3.8k

Countries citing papers authored by John W. Kugler

Since Specialization

Citations

This map shows the geographic impact of John W. Kugler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John W. Kugler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John W. Kugler more than expected).

Fields of papers citing papers by John W. Kugler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John W. Kugler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John W. Kugler. The network helps show where John W. Kugler may publish in the future.

Co-authorship network of co-authors of John W. Kugler

This figure shows the co-authorship network connecting the top 25 collaborators of John W. Kugler. A scholar is included among the top collaborators of John W. Kugler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John W. Kugler. John W. Kugler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jatoi, Aminah, Shaker R. Dakhil, Jeff A. Sloan, et al.. (2010). Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Supportive Care in Cancer. 19(10). 1601–1607. 42 indexed citations

Barton, Debra L., Edward J. Wos, Rui Qin, et al.. (2010). A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Supportive Care in Cancer. 19(6). 833–841. 195 indexed citations

Foster, Nathan R., Yingwei Qi, Qian Shi, et al.. (2010). Tumor response and progression‐free survival as potential surrogate endpoints for overall survival in extensive stage small‐cell lung cancer. Cancer. 117(6). 1262–1271. 93 indexed citations

Johnson, Elizabeth A., Randolph S. Marks, Sumithra J. Mandrekar, et al.. (2007). Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung Cancer. 60(2). 200–207. 57 indexed citations

Loprinzi, Charles L., Ralph Levitt, Debra L. Barton, et al.. (2006). Phase III Comparison of Depomedroxyprogesterone Acetate to Venlafaxine for Managing Hot Flashes: North Central Cancer Treatment Group Trial N99C7. Journal of Clinical Oncology. 24(9). 1409–1414. 86 indexed citations

Dy, Grace K., James R. Jett, Francois J. Geoffroy, et al.. (2006). Topotecan and Paclitaxel in Previously Treated Patients with Relapsed Small Cell Lung Cancer: Phase II Trial of the North Central Cancer Treatment Group. Journal of Thoracic Oncology. 1(3). 211–217. 5 indexed citations

D’Andre, Stacy D., Daniel J. Sargent, S. Stephen, et al.. (2005). 5-Fluorouracil–Based Chemotherapy for Advanced Colorectal Cancer in Elderly Patients: A North Central Cancer Treatment Group Study. Clinical Colorectal Cancer. 4(5). 325–331. 36 indexed citations

Long, Harry J., Robert A. Nelimark, Karl C. Podratz, et al.. (2005). Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium. Gynecologic Oncology. 100(3). 501–505. 10 indexed citations

Schaefer, Paul, Randolph S. Marks, Michelle R. Mahoney, et al.. (2003). . American Journal of Clinical Oncology. 26(3). 236–240. 1 indexed citations

10.

Schaefer, Paul, Randolph S. Marks, Michelle R. Mahoney, et al.. (2003). Randomized Phase II Study of Daily Versus Continuous-Infusion Schedules of Topotecan in the Treatment of Extensive-Stage Small Cell Lung Cancers. American Journal of Clinical Oncology. 26(3). 236–240. 9 indexed citations

11.

Jatoi, Aminah, Susan M. Geyer, Thomas K. Schulz, et al.. (2003). Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity. Lung Cancer. 43(3). 345–353. 36 indexed citations

12.

Jett, James R., Alan K. Hatfield, Shauna L. Hillman, et al.. (2003). Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive‐stage small cell lung carcinoma. Cancer. 97(10). 2498–2503. 17 indexed citations

13.

Markovic, Svetomir N., Vera J. Suman, Robert J. Dalton, et al.. (2002). Randomized, Placebo-Controlled, Phase III Surgical Adjuvant Clinical Trial of Megestrol Acetate (Megace) in Selected Patients With Malignant Melanoma. American Journal of Clinical Oncology. 25(6). 552–556. 9 indexed citations

14.

Loprinzi, Charles L., John W. Kugler, James A. Mailliard, et al.. (2000). Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. The Lancet. 356(9247). 2059–2063. 539 indexed citations breakdown →

15.

Creagan, Edward T., Vera J. Suman, Suresh Nair, et al.. (1998). Combined Levamisole With Recombinant Interleukin-2 (IL-2) in Patients With Advanced Renal Cell Carcinoma. American Journal of Clinical Oncology. 21(2). 139–141. 8 indexed citations

16.

Mani, Sridhar, John W. Kugler, James A. Knost, et al.. (1998). Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer. Investigational New Drugs. 16(3). 275–278. 27 indexed citations

17.

Buckner, Jan C., Loren D. Brown, John W. Kugler, et al.. (1995). Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. Journal of neurosurgery. 82(3). 430–435. 49 indexed citations

18.

Long, Harry J., H. Samuel Wieand, John W. Kugler, et al.. (1995). Phase II Trial of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced/Recurrent Carcinoma of the Uterine Cervix and Vagina. Gynecologic Oncology. 57(2). 235–239. 30 indexed citations

19.

Whitaker, William R. J., et al.. (1991). Fibrillary Glomerulonephritis: A Case Report. American Journal of Kidney Diseases. 18(1). 131–133. 6 indexed citations

20.

Windschitl, Harold E., Harry S. Wieand, James E. Krook, et al.. (1990). A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer. Cancer. 66(5). 853–856. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact